Market
How will Quanterix's annual revenue change in fiscal year 2025 post-Akoya acquisition?
3
Resolution / Starting Odds
Increase by more than 30% • 25%
Increase by 10-30% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Quanterix's fiscal year 2025 financial report
Story
Quanterix to Acquire Akoya Biosciences in All-Stock Deal for First Integrated Solution in Ultra-Sensitive Biomarker Detection
Jan 10, 2025, 11:37 AM
Quanterix Corporation has reached an agreement to acquire Akoya Biosciences in an all-stock transaction. This merger aims to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, enhancing capabilities in disease detection at various stages. Both companies are recognized for their contributions to life sciences, with Quanterix focusing on advanced biomarker detection technologies and Akoya specializing in spatial biology solutions. The deal is expected to combine their strengths and improve diagnostic capabilities in the healthcare sector.
View original story
Similar markets
No change • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease • 25%
11% to 15% • 25%
More than 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
More than $2 billion • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Less than $500 million • 25%
Revenue decreases by over 10% • 25%
Revenue increases by over 10% • 25%
Revenue increases by 0-10% • 25%
Revenue decreases by 0-10% • 25%
Growth above 10% • 25%
Growth below 5% • 25%
Growth 5-10% • 25%
No growth • 25%
Revenue increases by <5% • 25%
Revenue increases by >10% • 25%
Revenue increases by 5-10% • 25%
Revenue decreases • 25%
$1.71 billion to $1.79 billion • 25%
Above $1.89 billion • 25%
Below $1.71 billion • 25%
$1.79 billion to $1.89 billion • 25%
More than $4 billion • 25%
$3 billion to $3.5 billion • 25%
Less than $3 billion • 25%
$3.5 billion to $4 billion • 25%
5% to 10% • 25%
10% to 15% • 25%
Less than 5% • 25%
More than 15% • 25%